Urinary NO3 excretion and renal failure in indinavir-treated patients

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 8, 2006, Pages 1065-1070

  Eira, Marga ^a,b   Araujo, M ^a   Seguro, A C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Secretaria de Estado da Saude de Sao Paulo   (Brazil)

Author keywords

HIV; Indinavir; Nephrotoxicity; Nitric oxide

Indexed keywords

COTRIMOXAZOLE; CREATININE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; MAGNESIUM; NITRATE; NITRIC OXIDE; POTASSIUM; RITONAVIR; SODIUM; STAVUDINE; SULFADIAZINE; SULFUR DERIVATIVE; TRIACYLGLYCEROL; WATER; ZIDOVUDINE; BIOLOGICAL MARKER; NITRITE; OXAZINE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE DURATION; DIURESIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTURIA; MALE; NEPHROTOXICITY; PNEUMOCYSTOSIS; POTASSIUM EXCRETION; RISK ASSESSMENT; RISK FACTOR; SODIUM EXCRETION; STATISTICAL SIGNIFICANCE; TOXOPLASMOSIS; TREATMENT DURATION; URINALYSIS; URINARY EXCRETION; URINE LEVEL; URINE OSMOLALITY; URINE VOLUME; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; MIDDLE AGED; PROSPECTIVE STUDY; URINE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NITRATES; NITRITES; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 33747367894     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000800009     Document Type: Article

References (18)

1. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-1503.
2. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of anti-retroviral combination therapy. AIDS 1997; 11: 1731-1738.
3. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-153.
4. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
5. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37: 714-722.
6. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-125.
7. Saltel E, Angel JB, Futter NG, Walsh WG, O'Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000; 164: 1895-1897.
8. Dieleman JP, Gyssens IC, van der Ende ME, de MS, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-478.
9. Martinez F, Mommeja-Marin H, Estepa-Maurice L, Beaufils H, Bochet M, Daudon M, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13: 750-753.
10. Cattelan AM, Trevenzoli M, Naso A, Meneghetti F, Cadrobbi P. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000; 30: 619-621.
11. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, et al. Changes in renal function associated with indinavir. AIDS 1998; 12: F249-F254.
12. de AM, Seguro AC. Trimethoprim-suffamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. Antivir Ther 2002; 7: 181-184.
13. de AM, Seguro AC. Vasodilator agents protect against indinavir nephrotoxicity. Antivir Ther 2003; 8: 295-299.
14. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000; 169: 102-113.
15. Hampl V, Waters CL, Archer SL. Determination of nitric oxide by the chemiluminescence reaction with ozone. In: Feelisch M, Stamler JS (Editors), Methods in Nitric Oxide Research. New York: John Wiley & Sons Ltd., 1996, 309-318.
16. Grabe DW, Eisele G, Miller C, Singh J, Stein D. Indinavir-induced nephropathy. Clin Nephrol 1999; 51: 181-183.
17. Gagnon RF, Tecimer SN, Watters AK, Hatzakis GE, Tsoukas CM. The natural history of leukocyturia associated with indinavir treatment in HIV+ individuals. Am J Nephrol 2000; 20: 448-454.
18. Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, ten Veen JH, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162: 1493-1501.